COMMUNIQUÉS West-GlobeNewswire

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results
08/08/2024
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter [...]
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
08/08/2024
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across key subpopulations a six-month improvement [...]
BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.
08/08/2024
GRANTS, NEW MEXICO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that the Company has engaged an investment bank with vast experience to [...]
StateHouse Confirms Resumption of Trading
08/08/2024
SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, is pleased to [...]
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
08/08/2024
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate [...]
Vincerx Pharma Reports Second Quarter 2024 Financial Results
08/08/2024
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 [...]
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/08/2024
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we [...]
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/08/2024
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 ASCO 2024 [...]
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
08/08/2024
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board [...]
Lifeward to Report Second Quarter Financial Results on August 15, 2024
08/08/2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing [...]
CooperCompanies to Participate in Upcoming Investor Conferences
08/08/2024
SAN RAMON, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced its participation in the following upcoming investor conferences: 2024 Wells [...]
Voting Rights and Shares Capital of the Company
08/08/2024
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 08, 2024 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
08/08/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 08 août 2024 (GLOBE NEWSWIRE) -- Paris, France, le 8 août 2024 Place de cotation : [...]
Ikena Oncology Reports Second Quarter 2024 Financial Results
08/08/2024
Strong financial position with $145 million in cash and investments at close of second quarter BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial [...]
AMN Healthcare Announces Second Quarter 2024 Results
08/08/2024
Quarterly revenue of $741 million ; GAAP EPS of $0.42 and adjusted EPS of $0.98 DALLAS, Aug. 08, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for [...]
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
08/08/2024
Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective [...]
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
08/08/2024
— First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 — — KB-9558 IND-enabling studies for [...]
Sienna Senior Living Inc. Reports Strong Second Quarter 2024 Financial Results and Announces Publication of 2023-2024 ESG Report
08/08/2024
MARKHAM, Ontario, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2024. The [...]
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08/08/2024
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM [...]

Pages